bioAffinity's CyPath Lung Sales Surge 100% in Q3 2026

  • CyPath Lung sales grew over 100% through Q3 2026 compared to 2025.
  • Number of ordering physicians increased by 89% year-over-year.
  • Total tests delivered rose from 775 in Q3 2025 to 1,620 in Q3 2026.
  • New distribution agreement with Veteran-Owned AvMEDICAL targets government healthcare expansion.

The surge in CyPath Lung sales reflects growing clinical adoption of noninvasive lung cancer detection tools, particularly as more indeterminate pulmonary nodules are identified through screening. This growth aligns with broader industry trends toward earlier cancer detection and personalized medicine, with bioAffinity positioning itself as a key player in the diagnostic space. The company's strategic focus on expanding government healthcare access through partnerships like AvMEDICAL could further accelerate its market penetration.

Government Market Expansion
Whether the AvMEDICAL partnership can significantly expand CyPath Lung's reach within the VA system and other government healthcare programs.
Physician Adoption Trends
The pace at which new physicians continue to adopt CyPath Lung and whether existing users increase their utilization rates.
Regulatory Compliance
How evolving CLIA and FDA regulations may impact bioAffinity's ability to maintain and expand its LDT status for CyPath Lung.